Skip to main content
SpringerLink
Log in

HIV-Associated Multicentric Castleman’s Disease

  • Chapter
  • First Online:
HIV-associated Hematological Malignancies

  • 631 Accesses

Abstract

Multicentric Castleman’s disease (MCD) is a rare but potentially fatal lymphoproliferative disorder that shows a close association with human herpesvirus-8 (HHV-8) infection. Interleukin-6 dysregulation is thought to be fundamental to its pathogenesis. MCD is characterized by recurrent flares with fever, lymphadenopathy, splenomegaly, and heterogeneous systemic manifestations, associated with cytopenia, raised inflammatory markers, and high HHV-8 viral load in the blood. During the recent years, the widespread use of combination antiretroviral therapy and the introduction of rituximab have dramatically improved the treatment of HIV-MCD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alzahrani M, Hull MC, Sherlock C, Griswold D, Leger CS, Leitch HA. Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome. Leuk Lymphoma. 2015;56:1246–51.

    Article  CAS  PubMed  Google Scholar 

  2. Bérezné A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103:4368–9.

    Article  PubMed  Google Scholar 

  3. Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol. 1995;6:35–40.

    CAS  PubMed  Google Scholar 

  4. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol. 2011;29:2481–6.

    Article  PubMed  Google Scholar 

  5. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Int Med. 2007;147:836–9.

    Article  PubMed  Google Scholar 

  6. Bower M. How I, treat HIV-associated multicentric Castleman disease. Blood. 2010;116:4415–21.

    Article  CAS  PubMed  Google Scholar 

  7. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Retroviral-mediated transfer of interleukin-6 into hematopoietic cells of mice results in a syndrome resembling Castleman’s disease. Curr Top Microbiol Immunol. 1990;166:37–41.

    CAS  PubMed  Google Scholar 

  8. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: case no. 40231. N Eng J Med. 1954;250:1001–5.

    Article  CAS  Google Scholar 

  9. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling lymphoma. Cancer. 1956;9:822–30.

    Article  CAS  PubMed  Google Scholar 

  10. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97:2130–6.

    Article  CAS  PubMed  Google Scholar 

  11. Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007;60:1350–7.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–12.

    CAS  PubMed  Google Scholar 

  13. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB trial. J Clin Oncol. 2007;25:3350–6.

    Article  PubMed  Google Scholar 

  14. Gérard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012;119:2228–33.

    Article  PubMed  Google Scholar 

  15. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8 – specific CD8+ T cells. Blood. 2008;111:1387–95.

    Article  CAS  PubMed  Google Scholar 

  16. Hoffmann C, Schmid H, Müller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118:3499–503.

    Article  CAS  PubMed  Google Scholar 

  17. Jung CP, Emmerich B, Goebel FD, Bogner JR. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol. 2004;75:176–7.

    Article  PubMed  Google Scholar 

  18. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi’s sarcoma and primary effusion lymphoma. Curr Opin Oncol. 2005;17:447–55.

    Article  CAS  PubMed  Google Scholar 

  19. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman’s disease. Eur J Haematol. 2006;76:269–71.

    Article  PubMed  Google Scholar 

  20. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman’s disease by thalidomide. Am J Hematol. 2003;73:48–53.

    Article  PubMed  Google Scholar 

  21. Li H, Wang H, Nicholas J. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling. J Virol. 2001;75:3325–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Marcelin A-G, Motol J, Guihot A, et al. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J Infect Dis. 2007;196:1163–6.

    Article  PubMed  Google Scholar 

  23. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996;274:1739–44.

    Article  CAS  PubMed  Google Scholar 

  24. Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10:25–35.

    PubMed  Google Scholar 

  25. Nagao A, Nakazawa S, Hanabusa H. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol. 2014;7:10.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32:1006–12.

    Article  PubMed  Google Scholar 

  27. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–32.

    Article  CAS  PubMed  Google Scholar 

  28. Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman’s disease. Int J STD AIDS. 2003;14:61–2.

    Article  CAS  PubMed  Google Scholar 

  29. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99:2331–6.

    Article  CAS  PubMed  Google Scholar 

  30. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood. 2000;96:2069–73.

    CAS  PubMed  Google Scholar 

  31. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61–7.

    Article  CAS  PubMed  Google Scholar 

  32. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4:16–21.

    Article  PubMed  Google Scholar 

  33. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2013;122:4189–98.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012;3:73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20:775–9.

    Article  CAS  PubMed  Google Scholar 

  36. Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood. 2007;110:4132–3.

    Article  CAS  PubMed  Google Scholar 

  37. Scott D, Cabral L, Harrington Jr WJ. Treatment of HIV-associated multicentric Castleman’s disease with oral etoposide. Am J Hematol. 2001;66:148–50.

    Article  CAS  PubMed  Google Scholar 

  38. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80.

    CAS  PubMed  Google Scholar 

  39. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood. 2011;118:271–5.

    Article  CAS  PubMed  Google Scholar 

  40. Stone K, Woods E, Szmania SM, et al. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One. 2013;8:e54610.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Talat N, Schulte KM. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16:1316–24.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Tedeschi R, Marus A, Bidoli E, Simonelli C, De Paoli P. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol. 2008;43:255–9.

    Article  CAS  PubMed  Google Scholar 

  43. Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124:3544–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Uldrick TS, Wang V, O’Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51:350–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966–74.

    Article  PubMed  Google Scholar 

  47. Zietz C, Bogner JR, Goebel FD, Lohrs U. An unusual cluster of cases of Castleman’s disease during HAART for AIDS. N Engl J Med. 1999;340:1923–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infektionsmedizinisches Centrum Hamburg (ICH), Hamburg, Germany

    Christian Hoffmann MD

  2. Hôpital Saint-Louis, AP-HP, and EA3963, University Paris Diderot, Paris, France

    Eric Oksenhendler & Laurence Gérard

Authors
  1. Christian Hoffmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Oksenhendler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurence Gérard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Hoffmann MD .

Editor information

Editors and Affiliations

  1. Department of Hematology and Oncology, Red Cross Hospital, Uni of Munich, Munich, Germany

    Marcus Hentrich

  2. Dept. of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Stefan K. Barta

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hoffmann, C., Oksenhendler, E., Gérard, L. (2016). HIV-Associated Multicentric Castleman’s Disease. In: Hentrich, M., Barta, S. (eds) HIV-associated Hematological Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-26857-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26857-6_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26855-2

  • Online ISBN: 978-3-319-26857-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation